National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pembrolizumab (Keytruda ®) for Classical Hodgkin Lymphoma

Pembrolizumab (Keytruda®) is indicated as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.


NCPE Assessment Process Complete
Rapid review commissioned 06/12/2017
Rapid review completed 21/12/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended at the submitted price

The HSE has approved reimbursement following confidential price negotiations – November 2018.